Tonghua Golden-Horse Pharmaceutical Industry CoLtd Balans Gezondheid

Financiële gezondheid criteriumcontroles 1/6

Tonghua Golden-Horse Pharmaceutical Industry CoLtd heeft een totaal eigen vermogen van CN¥2.3B en een totale schuld van CN¥1.7B, wat de schuld-eigenvermogensverhouding op 73.1% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥4.5B en CN¥2.1B. De EBIT Tonghua Golden-Horse Pharmaceutical Industry CoLtd is CN¥124.6M waardoor de rentedekking 1.6 is. Het heeft contanten en kortetermijnbeleggingen van CN¥181.1M.

Belangrijke informatie

73.1%

Verhouding schuld/eigen vermogen

CN¥1.69b

Schuld

Rente dekkingsratio	1.6x
Contant	CN¥181.12m
Aandelen	CN¥2.32b
Totaal verplichtingen	CN¥2.15b
Totaal activa	CN¥4.47b

Recente financiële gezondheidsupdates

Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) Seems To Use Debt Quite Sensibly

Jun 03

Recent updates

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd's (SZSE:000766) Popularity With Investors Is Under Threat From Overpricing

Aug 20

Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) Seems To Use Debt Quite Sensibly

Jun 03

Should You Be Adding Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) To Your Watchlist Today?

May 12

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (SZSE:000766) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Mar 06

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥1.0B ) 000766 } overtreffen de korte termijn passiva ( CN¥512.0M ).

Langlopende schulden: De kortetermijnactiva van 000766 ( CN¥1.0B ) dekken de langetermijnschulden ( CN¥1.6B ) niet.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 65.3% ) 000766 wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van 000766 is de afgelopen 5 jaar gestegen van 11.7% naar 73.1%.

Schuldendekking: De schuld van 000766 wordt niet goed gedekt door de operationele kasstroom ( 11.5% ).

Rentedekking: De rentebetalingen van 000766 op haar schulden worden niet goed gedekt door EBIT ( 1.6 x dekking).

Tonghua Golden-Horse Pharmaceutical Industry CoLtd Balans Gezondheid

Financiële gezondheid criteriumcontroles 1/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) Seems To Use Debt Quite Sensibly

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.012 (vs CN¥0.005 in 3Q 2023)

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd to Report Q3, 2024 Results on Oct 21, 2024

Second quarter 2024 earnings released: EPS: CN¥0.003 (vs CN¥0.004 in 2Q 2023)

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd's (SZSE:000766) Popularity With Investors Is Under Threat From Overpricing

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd to Report First Half, 2024 Results on Aug 21, 2024

Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) Seems To Use Debt Quite Sensibly

New minor risk - Share price stability

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd, Annual General Meeting, Jun 17, 2024

Should You Be Adding Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) To Your Watchlist Today?

Full year 2023 earnings released: EPS: CN¥0.05 (vs CN¥0.03 in FY 2022)

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd to Report Q1, 2024 Results on Apr 23, 2024

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (SZSE:000766) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: EPS: CN¥0.005 (vs CN¥0.005 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.004 (vs CN¥0.002 in 2Q 2022)

New minor risk - Share price stability

Now 23% undervalued

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Approves Board Elections

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd to Report First Half, 2023 Results on Aug 21, 2023

Now 21% undervalued after recent price drop

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd, Annual General Meeting, Jun 21, 2023

Now 22% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥0.03 (vs CN¥0.04 in FY 2021)

Now 20% undervalued after recent price drop

Now 21% undervalued

Now 20% undervalued

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.005 (vs CN¥0.007 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.002 (vs CN¥0.02 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.006 (vs CN¥0.004 in 1Q 2021)

High number of new and inexperienced directors

Full year 2021 earnings released: EPS: CN¥0.04 (vs CN¥0.37 loss in FY 2020)

Third quarter 2021 earnings released: CN¥0.007 loss per share (vs CN¥0.09 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.02 (vs CN¥0.033 loss in 2Q 2020)

Full year 2020 earnings released: CN¥0.37 loss per share (vs CN¥2.11 loss in FY 2019)

New 90-day high: CN¥4.26

New 90-day low: CN¥3.13

New 90-day low: CN¥3.56

Tibet Dechangtai Pharmaceutical Technology Co., Ltd. signed a share transfer agreement to acquire Lhasa Yongkang Medicine Co., Ltd. from Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (SZSE:000766) for CNY 5.1 million.

Third quarter earnings released

New 90-day low: CN¥3.87

New 90-day low: CN¥4.54

New 90-day low: CN¥4.62

New 90-day high - CN¥5.58

First half earnings released

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven